MüllerFTaubmannJBucciL, et al. CD19 CAR T-cell therapy in autoimmune disease—A case series with follow-up. N Engl J Med2024; 390: 687–700.
2.
GrecoRAlexanderTDel PapaN, et al. Innovative cellular therapies for autoimmune diseases: Expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. eClinicalMedicine2024; 69: 102476.
3.
BrittainGRoldanEAlexanderT, et al. The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases. Ann Neurol2024; 96: 441–452.
4.
MackensenAMüllerFMougiakakosD, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med2022; 28(10): 2124–2132. Erratum in: Nat Med. 2023; 29(11): 2956.
5.
TurCEcksteinMVeldenJ, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis2025; 84(1): 106–114.
6.
RichterJFischbachFPfefferLK, et al. CD19-directed CAR T cell therapy in 4 patients with refractory multiple sclerosis. Blood2024; 144(Suppl. 1): 2073.
7.
HagenMMüllerFWirschingA, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: An observational study. Lancet Rheumatol2025; 77(6): e424–e433.
8.
MougiakakosDMeyerEHSchettG. CAR T cells in autoimmunity: Game changer or stepping stone?Blood2025; 145(17): 1841–1849.
9.
DingLCuiJHuY, et al. Changes of T lymphocyte subsets after CAR-T cell therapy and its clinical significance. Blood2018; 132(Suppl. 1): 1423.
10.
JoyceJAFearonDA. T cell exclusion, immune privilege, and the tumor microenvironment. Science2015; 348: 7480.
